IDO1 and neoplasm: During treatment, predominant infiltration of IDO1-expressing tumor-associated macrophages and significantly elevated plasma Kyn/Trp ratio both indicate robust IDO1 pathway activation that likely counteracts PD-1 inhibition efficacy [240].